These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 17210459)

  • 1. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
    Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
    Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
    Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
    Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
    Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides.
    Dijkgraaf I; Kruijtzer JA; Liu S; Soede AC; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):267-73. PubMed ID: 16909226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
    Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
    Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
    Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
    J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide.
    Dijkgraaf I; Terry SY; McBride WJ; Goldenberg DM; Laverman P; Franssen GM; Oyen WJ; Boerman OC
    Contrast Media Mol Imaging; 2013; 8(3):238-45. PubMed ID: 23606427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
    Chakraborty S; Shi J; Kim YS; Zhou Y; Jia B; Wang F; Liu S
    Bioconjug Chem; 2010 May; 21(5):969-78. PubMed ID: 20387808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides.
    Zheng Y; Ji S; Tomaselli E; Yang Y; Liu S
    Nucl Med Biol; 2015 Feb; 42(2):137-45. PubMed ID: 25459111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.
    Shi J; Kim YS; Chakraborty S; Zhou Y; Wang F; Liu S
    Amino Acids; 2011 Nov; 41(5):1059-70. PubMed ID: 20052508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides.
    Dijkgraaf I; Yim CB; Franssen GM; Schuit RC; Luurtsema G; Liu S; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):128-37. PubMed ID: 20857099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.
    Cai W; Chen K; Li ZB; Gambhir SS; Chen X
    J Nucl Med; 2007 Nov; 48(11):1862-70. PubMed ID: 17942800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
    Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
    J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
    Ahmadi M; Sancey L; Briat A; Riou L; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP
    Cancer Biother Radiopharm; 2008 Dec; 23(6):691-700. PubMed ID: 19111043
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.